Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 1999

View Archived Issues

Novel MSI delivery system tested in breakthrough pain therapy

Vitamin D analogue Ro-25-6760 is a promising treatment for colon cancer

Company Profile: Redox

Vion and EPTTCO to develop new cancer treatments based on TAPET delivery system

Second HIV fusion inhibitor developed at Trimeris given fast track designation

Lundbeck: Annual Report 1998

Ophidian: Q2 1999 highlights

New vitronectin receptor ligands emerge from collaborative research at HMR and Genentech

Neuropeptide Y antagonists specifically claimed for use in cardiovascular disorders

Corvas and Schering-Plough extend HCV agreement

Bayer's new CETP inhibitors described in recently published patent

Tokyo Tanabe discloses new antimuscarinic agents

Onyvax licenses anticancer vaccine from CRCT

Antirotavirus polymers in development at GelTex

Abbott prepares semisynthetic rapamycin analogues with reduced half-lives

ImClone commences second phase III trial of C225

SmithKline Beecham describes new series of CCR5 receptor modulators

Preliminary clinical results reported at ASCO for Tularik microtubule inhibitor

XR-9576: first clinical results indicate efficacy, safety and favorable pharmacokinetics

News from ASCO: Genta's G-3139 is effective in treating various cancer types

Immune Response to collaborate with Univ. of Maryland on chemokine research

ASCO highlights: phase I clinical trial results with oral R-115777 alone and in combination regimen

Introgen Therapeutics and RPR Gencell sign CRADA with NCI

Takeda reports discovery of TAK-779, a potent anti-HIV agent with a novel mechanism

Novartis presents first clinical results for Abl tyrosine kinase inhibitor CGP-57148

Novel intranasally administered small peptide shows good efficacy and safety in AIDS-related KS

News from ASCO: clinical pharmacology of Bay-12-9566 assessed in cancer patients

Alcon launches emedastine in U.K. for treatment of seasonal allergic conjunctivitis

ZD-0473 exhibits favorable toxicity profile in phase I studies in solid tumor patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...